ALFA Finder| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 90.7 | 25.5 | 21.8 |
| Other income | 3.0 | 0.3 | 2.4 |
| Total income | 93.7 | 25.9 | 24.2 |
| Profit before exceptional items & tax | 3.5 | 0.6 | 0.6 |
| Profit before tax | 3.5 | 0.6 | 0.6 |
| Net profit | 2.6 | 0.4 | 0.2 |
| Operating margin | 3.7% | 2.3% | 2.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1200.00% |
|---|---|
| Net profit, quarter on quarter | +550.00% |
| Revenue, year on year | +316.10% |
BSE results filing, BSE: 542934. Figures extracted from the filing.
Chandra Bhagat Pharma Ltd: key numbers
- Share price
- ₹57.85
- Market cap
- ₹43.65 Cr
- Revenue (annual)
- ₹116.3 Cr
- Net profit (annual)
- ₹3.05 Cr
- P/E (TTM)
- 14.3×Sector 43.8×
- Promoter holding
- 73.02%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chandra Bhagat Pharma Ltd
All →Chandra Bhagat Pharma Board Meeting Date
Chandra Bhagat Pharma Limited has intimated a board meeting on 13 November 2026 to consider unaudited standalone half-yearly financial results for the period ended September 2026. The trading window closes from 1 October to 16 November 2026.
Chandra Bhagat Pharma Convertible Warrants
Chandra Bhagat Pharma allotted 50 lakh convertible warrants worth ₹21.90 Crore to seven promoter group members. Allotment was completed on 22 October 2026.
- Value
- ₹21.90 Cr
Chandra Bhagat Pharma Convertible Warrants
Chandra Bhagat Pharma allotted 66 lakh convertible warrants at Rs.44 each, raising Rs.7.26 Crore from 9 allottees. Warrants are convertible 1:1 into equity shares within 18 months.
- Value
- ₹7.26 Cr
Chandra Bhagat Pharma Other Announcement
Chandra Bhagat Pharma Ltd filed a certificate for non-applicability of corporate governance requirements for the September 2026 quarter. This exemption applies to SME-listed entities.
Chandra Bhagat Pharma Preferential Issue
Chandra Bhagat Pharma received BSE in-principle approval for a preferential issue of 66,00,000 warrants at Rs. 44 each. Total issue value is approximately Rs. 2.90 Crore.
- Value
- ₹2.90 Cr
Chandra Bhagat Pharma Management Change
Ms. Rajani Dawani has resigned from her position as Company Secretary and Compliance Officer of Chandra Bhagat Pharma Limited, effective September 30, 2026.